Skip to content
lifestyle.cfxmagazine.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Business
Latest Business News
Delhi Most Affordable Flats Range is available to sale know who can purchase
issuewire
September 7, 2025
TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
businesswire
September 7, 2025
20TH ANNUAL SURF DOG SURF-A-THON IS READY TO MAKE A SPLASH
prnewswire
September 7, 2025
BEAUTE SEOUL Bonnet Dryer: Curl-Centered K-Beauty At-Home Hair Care
24-7 Press
September 7, 2025
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
businesswire
September 7, 2025
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
businesswire
September 7, 2025
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
businesswire
September 7, 2025
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
businesswire
September 7, 2025
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
businesswire
September 7, 2025
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
businesswire
September 7, 2025
Prev
1
…
35,943
35,944
35,945
35,946
35,947
…
38,298
Next
Channels
Follow Us
X
LinkedIn
